Page last updated: 2024-10-30

labetalol and Experimental Mammary Neoplasms

labetalol has been researched along with Experimental Mammary Neoplasms in 1 studies

Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Gurrapu, S1
Jonnalagadda, SK1
Alam, MA1
Ronayne, CT1
Nelson, GL1
Solano, LN1
Lueth, EA1
Drewes, LR1
Mereddy, VR1

Other Studies

1 other study available for labetalol and Experimental Mammary Neoplasms

ArticleYear
Coumarin carboxylic acids as monocarboxylate transporter 1 inhibitors: In vitro and in vivo studies as potential anticancer agents.
    Bioorganic & medicinal chemistry letters, 2016, 07-15, Volume: 26, Issue:14

    Topics: Animals; Antineoplastic Agents; Carboxylic Acids; Cell Line, Tumor; Cell Proliferation; Coumarins; D

2016